Table 2.

Hazard ratio of Flu/Bu4 compared with Flu/Bu2

	Univariate analysis			Multivariable analysis			PS matching analysis
	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
Overall survival	2.10	1.56–2.84	< 0.001	1.91	1.36–2.69	< 0.001	2.13	1.30–3.50	0.003
Progression-free survival	1.59	1.20–2.10	0.001	1.43	1.05–1.96	0.025	1.40	0.91–2.16	0.128
Nonrelapse mortality	2.02	1.28–3.18	0.002	1.95	1.14–3.34	0.015	1.86	1.03–3.37	0.041
Relapse	1.14	0.83–1.58	0.420	1.14	0.80–1.63	0.460	1.13	0.74–1.71	0.570
Neutrophil engraftment	0.82	0.67–1.01	0.065	0.89	0.69–1.14	0.340	0.92	0.70–1.22	0.550
Platelet engraftment	0.76	0.59–0.97	0.030	0.80	0.58–1.10	0.160	1.01	0.73–1.39	0.960
Grade II–IV acute GVHD	1.22	0.84–1.77	0.290	1.25	0.84–1.88	0.270	1.47	0.92–2.35	0.100
Grade III–IV acute GVHD	1.87	0.95–3.69	0.070	1.67	0.79–3.55	0.180	3.18	1.04–9.75	0.043
Chronic GVHD	0.59	0.37–0.93	0.022	0.62	0.38–1.01	0.050	0.72	0.42–1.25	0.250
Extensive chronic GVHD	0.63	0.36–1.08	0.093	0.71	0.38–1.32	0.280	0.85	0.44–1.65	0.630

CI confidence interval, FluBu2 fludarabine with reduced-intensity busulfan, FluBu4 fludarabine with myeloablative busulfan, GVHD graft versus host disease, HR hazard ratio, PS propensity score